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Peroxisomes play an important role in the biosynthesis of bile acids because a peroxisomal β-oxidation step is required for the formation of the
mature C24-bile acids from C27-bile acid intermediates. In addition, de novo synthesized bile acids are conjugated within the peroxisome. In this
review, we describe the current state of knowledge about all aspects of peroxisomal function in bile acid biosynthesis in health and disease. The
peroxisomal enzymes involved in the synthesis of bile acids have been identified, and the metabolic and pathologic consequences of a deficiency
of one of these enzymes are discussed, including the potential role of nuclear receptors therein.
© 2006 Elsevier B.V. All rights reserved.Keywords: Peroxisomal β-oxidation; Nuclear receptors; C27-bile acid intermediates; Peroxisome deficiency disorders1. Introduction
In the early 1980s, the first clues were obtained indicating the
importance of peroxisomes in the biosynthesis of bile acids. In
1978, Hansen et al. were the first to report a defect in bile acid
synthesis in Zellweger syndrome [1]. At the time, however, this
defect was attributed to the mitochondrial abnormalities
associated with this disorder. Later it became clear that these
mitochondrial abnormalities are only secondary and that the bile
acid biosynthesis deficiency in these patients is caused by the
primary defect in this disorder, i.e. the absence of functional
peroxisomes. The accumulation of C27-bile acid intermediates
showed that Zellweger patients were not able to cleave the side-
chain of these precursors and thus could not form mature C24-
bile acids. After the identification of a fatty acid oxidizing
system in peroxisomes, the subcellular localization of this side-
chain cleavage was reinvestigated and was shown to occur in
peroxisomes [2,3]. Many reports on bile acid abnormalities in
patients with a peroxisome deficiency followed and even
prenatal diagnosis of Zellweger syndrome by measurement of
bile acids in amniotic fluid can be done reliably [4,5]. In the
1990s, next to the classical set of fatty acid oxidation enzymes, a
second set of fatty acid oxidation enzymes was identified in the⁎ Corresponding author. Tel.: +31 20 5665958; fax: +31 20 6962596.
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role of the individual enzymes in the different peroxisomal
functions, including bile acid biosynthesis. Not only in vitro
studies with purified and recombinant enzymes attributed to the
resolution but also the identification of patients with single
enzyme deficiencies associated with bile acid abnormalities. In
this paper, the current knowledge about the peroxisomal steps in
bile acid biosynthesis, including the role of nuclear receptors
(NRs) in their control, but also the gaps in this knowledge will
be reviewed. In addition, the bile acid abnormalities in
peroxisomal disorders and mouse models for peroxisomal
disorders are discussed, including the consequences of these
bile acid abnormalities.
2. Bile acid biosynthesis
Cholesterol is converted into bile acids via multiple
pathways which involve many different enzymes. Many of
these enzymes are predominantly expressed in the liver and are
localized in several different subcellular compartments. Ap-
proximately 500 mg of cholesterol is converted into bile acids
each day in the adult human liver. Bile acid biosynthesis
involves modification of the ring structure of cholesterol,
oxidation and shortening of the side chain, and finally
conjugation of the bile acid with an amino acid. All these
steps and the enzymes involved are reviewed in detail by
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with the conversion of cholesterol into 7α-hydroxycholesterol
by cholesterol 7α-hydroxylase (CYP7A1). This is a microsomal
cytochrome P450 enzyme localized exclusively in the liver. Its
expression is highly regulated and shows a strong diurnal
rhythm. The classic pathway involving CYP7A1 is the major
pathway in bile acid biosynthesis because its contribution to
total bile acid synthesis is ∼ 90% humans and ∼ 75% in mice
[6]. A schematic overview of the classic pathway is depicted in
Fig. 1. In the acidic pathway, oxysterols rather than cholesterol
serve as substrates for 7α-hydroxylation. Sterol 27-hydroxy-
lase, a mitochondrial cytochrome P450 (CYP27A1), forms
predominantly 27-hydroxycholesterol but can also hydroxylate
cholesterol at carbons 24 and 25. Alternatively, 24- and 25-
hydroxycholesterol are also the product of separate cholesterol
24- and 25-hydroxylases. To be converted into bile acids, these
oxysterols must undergo 7α-hydroxylation. Oxysterol 7α-
hydroxylase (CYP7B1) catalyzes the conversion of 27-hydro-
xycholesterol and 25-hydroxycholesterol, and is highly
expressed in liver [6]. The CYP39A1 oxysterol 7α-hydroxylase
acts on 24-hydroxycholesterol [6]. The acidic pathway is
responsible for the remaining bile acid synthesis (∼10% in
humans and ∼25% in mice) [6].
The next step in the ring structure modifications involves
isomerization of the double bond from the 5 to the 4 positionFig. 1. Schematic representation of the classic bile acid biosynthesis pathway which i
total bile acid synthesis in mice. The peroxisomal steps of the pathway are shown i
steroid oxidoreductase; CYP8B1, sterol 12α-hydroxylase; AKR1D1, Δ4-3-oxosteroi
27-hydroxylase.and the oxidation of the 3β-hydroxyl-group to a 3-oxo-group.
This step is catalyzed by the microsomal 3β-hydroxy-Δ5-C27-
steroid oxidoreductase (HSD3B7), which can only handle 7α-
hydroxylated intermediates derived from both cholesterol and
oxysterols [6]. At this point in the biosynthesis pathway, the
intermediates can be acted upon by sterol 12α-hydroxylase
(CYP8B1), and this will decide the fate of the produced bile
acid [6]. If handled by CYP8B1, another microsomal
cytochrome P450, the final product will be cholic acid
(CA), whereas otherwise chenodeoxycholic acid (CDCA) (in
humans) or muricholic acid (mCA) (in mice) will be formed.
Subsequently, the products of HSD3B7, whether or not 12α-
hydroxylated, are subject to reduction of the double bond by
the enzyme Δ4-3-oxosteroid 5β-reductase (AKR1D1), which
is a cytosolic enzyme [6]. The final step of the ring
modifications involves reduction of the 3-oxo-group to an
alcohol-group and is catalyzed by 3α-hydroxysteroid dehy-
drogenase (AKR1C4) [6].
After the ring modifications, the sterol side chain is oxidized,
activated and shortened by cleaving off propionyl-CoA. The
first steps of this process are catalyzed by CYP27A1, which is
the same mitochondrial enzyme that can initiate bile acid
biosynthesis through formation of 27-hydroxycholesterol. The
enzyme introduces a hydroxyl-group at carbon 27 and then
oxidizes this group to an aldehyde and then to a carboxylic acids responsible for ∼ 90% of the total bile acid synthesis in humans and ∼ 75% of
n Fig. 2. CYP7A1, cholesterol 7α-hydroxylase; HSD3B7, 3β-hydroxy-Δ5-C27-
d 5β-reductase; AKR1C4, 3α-hydroxysteroid dehydrogenase; CYP27A1, sterol
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3α,7α-dihydroxycholestanoic acid (DHCA) and 3α,7α,12α-
trihydroxycholestanoic acid (THCA) (Fig. 2), which subse-
quently have to be activated to their CoA-ester. Two enzymes
have been identified which can perform this reaction. The first isFig. 2. Schematic representation of the peroxisomthe very long-chain acyl-CoA synthetase (VLCS, encoded by
SLC27A2) localized at the endoplasmic reticulum and in the
peroxisome, and the second is the bile acyl-CoA synthetase
(BACS, also called the very long-chain acyl-CoA synthetase
homolog 2, encoded by SLC27A5) exclusively localized at theal steps involved in bile acid biosynthesis.
1430 S. Ferdinandusse, S.M. Houten / Biochimica et Biophysica Acta 1763 (2006) 1427–1440endoplasmic reticulum [7]. BACS, which is only present in
liver, also displays activity towards C24-bile acids and is thought
to be involved in the activation of the bile acids which return to
the liver via the enterohepatic circulation after deconjugation in
the small intestine [7]. At the moment, it is unclear which of the
two synthetases capable of activating C27-bile acids is in vivo
responsible for the CoA-ester formation of DHCA and THCA,
and whether this occurs at the endoplasmic reticulum or in the
peroxisome. Although activation within the peroxisome is an
attractive hypothesis because the subsequent shortening of the
side-chain also occurs within the peroxisome, only a very small
portion of VLCS is localized in the peroxisome increasing the
likelihood of microsomal activation [8]. To date, no THC-CoA
synthetase activity has been demonstrated in the peroxisome
[9,10]. This would imply that DHC-CoA/THC-CoA have to be
transported into the peroxisome. ATP-dependent transport of
THC-CoA, and not of THCA, across rat liver peroxisomal
membranes has been shown by demonstration of subsequent
production of CA. These studies, however, were performed with
peroxisomes purified by differential centrifugation followed by
isopycnic centrifugation in sucrose [11] and it is well known
that purified peroxisomes are leaky. Unequivocal evidence for
transport of the C27-bile acid intermediates, either as free acid or
as CoA-ester, is therefore still lacking and the responsible
transporter remains to be identified.
3. Peroxisomal steps in bile acid biosynthesis
After the discovery that THCA is metabolized in the
peroxisome to CA by side-chain cleavage, all investigations
were aimed at identifying the underlying mechanism. Especial-
ly since 3α,7α,12α,24-tetrahydroxy-5β-cholestanoic acid was
identified as likely intermediate [1,12], a mechanism similar to
fatty acid oxidation seemed very attractive. Indeed, the
conversion of THCA to CA in peroxisomes was shown to be
dependent on all the co-factors for fatty acid β-oxidation: ATP,
Mg2+, CoA, FAD and NAD+[2,3,13]. Studies with 18O2 and
2H2O revealed that the reactions involved desaturation followed
by hydration, and were consistent with a reaction mechanism
analogous to that of fatty acid β-oxidation [13]. With the
identification and characterization of all the enzymes involved
in peroxisomal β-oxidation, the role of the individual enzymes
in bile acid synthesis has become clear. See for details on the
peroxisomal β-oxidation enzymes Wanders and Waterham [14].
The peroxisomal steps in bile acid biosynthesis are depicted in
Fig. 2. The first peroxisomal enzyme required for the conversion
ofDHC-CoA andTHC-CoA to chenodeoxycholoyl-CoA (CDC-
CoA) and choloyl-CoA (CA-CoA), respectively, is α-methyla-
cyl-CoA racemase (AMACR) [15,16]. Its activity is necessary
for this conversion, because only (25R)-stereoisomers are formed
by CYP27A1 [17,18], whereas the peroxisomal β-oxidation
system can only handle (25S)-isomers [19,20]. Thus, AMACR
racemizes (25R)-DHC-CoA and (25R)-THC-CoA to their
respective (S)-isomers, allowing subsequent β-oxidation of
these substrates. In mouse and rat, THC-CoA oxidase (encoded
by Acox2) oxidizes the CoA-esters of the C27-bile acid
intermediates [21,22]. Its ortholog in humans is the branched-chain acyl-CoA oxidase (BCOX, encoded by ACOX2) [23],
which is involved in the oxidation of the C27-bile acid
intermediates and of pristanoyl-CoA that has a methyl-group at
the 2 position just like the side-chains of DHCA and THCA. The
acyl-CoA oxidase desaturates (25S)-THC-CoA to 3α,7α,12α-
trihydroxy-5β-cholest-24-en-26-oyl-CoA (24(E)-ene-THC-
CoA). Because β-oxidation of the side-chain of DHC-CoA is
analogous to that of THC-CoA, only the intermediates of THC-
CoA will be described here. The two subsequent reactions are
catalyzed by D-bifunctional protein (DBP, also called multi-
functional protein 2, multifunctional enzyme II, or D-peroxi-
somal bifunctional enzyme, encoded by HSD17B4). DBP
consists of multiple functional units and is a stereospecific
enzyme. Its hydratase unit converts 24(E)-ene-THC-CoA
exclusively into (24R,25R)-3α,7α,12α,24-tetrahydroxy-5β-
cholestanoyl-CoA (24-OH-THC-CoA) [24–27], which is con-
verted into 3α,7α,12α-trihydroxy-24-keto-5β-cholestanoyl-
CoA (24-keto-THC-CoA) by the dehydrogenase unit of DBP
[24–26]. Finally, sterol carrier proteinX (SCPx) cleaves 24-keto-
THC-CoA to CA-CoA and propionyl-CoA [28–30].
The last step in bile acid biosynthesis involves conjugation
of CDC-CoA and CA-CoAwith an amino acid. This reaction is
catalyzed by the bile acyl-CoA: amino acid N-acyltransferase
(BAAT), which is predominantly expressed in liver and is
localized in peroxisomes and the cytosol [31–36]. This dual
localization suggests that the peroxisomal BAAT is responsible
for conjugation of the newly formed primary bile acids within
the peroxisome, whereas the cytosolic BAAT will be involved
in reconjugation of the recycled primary and secondary bile
acids that have been deconjugated in the gut. Mouse BAAT is
only active with taurine [37], but human and rat BAAT can
conjugate bile acids with both taurine and glycine
[31,32,38,39]. The ratio of glycine to taurine conjugated bile
acids in humans is solely dependent on the relative abundance
of the two amino acids [6]. After conjugation, the bile acids will
have to be transported from the peroxisome by a yet
unidentified transporter and will then be excreted from the
hepatocyte into the bile.
4. Alternative pathways for bile acid biosynthesis
Studies on bile acid abnormalities in patients with a
deficiency of one of the enzymes involved in bile acid
biosynthesis have shown that alternative pathways for bile
acid formation must exist. Although the relative contribution of
these pathways will be minimal if the major pathway functions
normally, they can contribute substantially to bile acid synthesis
in case of defects. There is both a peroxisomal alternative
pathway and a pathway that does not require any peroxisomal
enzymes at all.
The proposed alternative pathway localized in peroxisomes
involves the other peroxisomal bifunctional protein, LBP
(also called multifunctional protein 1, multifunctional enzyme
I, or L-peroxisomal bifunctional enzyme, encoded by EH-
HADH) and AMACR [40] (see Fig. 3). 24(E)-ene-THC-CoA
is normally hydrated to (24R,25R)-24-OH-THC-CoA by DBP,
but can also be converted to (24S,25S)-24-OH-THC-CoA by
Fig. 3. Schematic representation of the peroxisomal steps in bile acid
biosynthesis, including potential alternative pathways indicated by dashed
arrows. The major peroxisomal pathway involves AMACR, BCOX, DBP (both
the hydratase and dehydrogenase unit of DBP) and SCPx. LBP and AMACR
take over the function of DBP in the alternative pathway. DBP activity is also not
necessary when (24S)-OH, (25R)-THC-CoA is formed via 24-hydroxylation of
cholesterol.
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is, however, not a substrate for the dehydrogenase unit of
LBP or DBP [25,41], but AMACR can convert it to the
(24S,25R)-isomer [40] which can be handled by the
dehydrogenase unit of LBP [41]. In addition, LBP will be
involved in the synthesis of bile acids from (24S)-hydroxycho-
lesterol as formed by cholesterol 24-hydroxylase which is
predominantly expressed in mammalian brain. The (24S)-
hydroxycholesterol is excreted across the blood–brain barrier
into the circulation and is important for the elimination of
cholesterol from the brain [42,43]. However, humans produce 6–
7 mg of (24S)-hydroxycholesterol per day, of which ∼3.5 mg is
catabolized to bile acids, whereas ∼500 mg of bile acids are
synthesized per day [6]. This indicates that, although this
pathway is important for the turnover of cholesterol in the brain, it
contributes little to overall bile acid synthesis. In case of a
deficiency of DBP or AMACR the alternative pathways
involving LBP could be significant however. Attempts to
determine the importance of this pathway in vivo by studying
the bile acids abnormalities in LBP:DBP double knockout mice
have been unsuccessful until now, because these animals turned
out to have a peroxisomal import defect [34]. Details about this
study will be discussed below.
In addition to the major pathways involving the mitochon-
drial CYP27A1 and the peroxisomal β-oxidation enzymes,
there is an alternative microsomal plus cytosolic pathway for the
cleavage of the steroid side-chain of 5β-cholestane-3α,7α,12α-
triol [44–47]. The pathway starts with microsomal 25-
hydroxylation of 5β-cholestane-3α,7α,12α-triol followed by
an additional 24-hydroxylation to yield 5β-cholestane-
3α,7α,12α,24S,25-pentol. This compound subsequently is
oxidized to a ketone and the 3-carbon side-chain is cleaved
off as acetone by cytosolic enzymes. This 25-hydroxylase
pathway is only active on 12α-hydroxylated compounds, thus
CDCA is never formed, and its contribution to overall bile acid
biosynthesis is less than 5% in human and rat [45–47].5. Bile acid abnormalities in peroxisomal disorders
5.1. Peroxisome deficiency disorders
Analysis of plasma bile acids from children with a
peroxisome deficiency disorder, including Zellweger syndrome,
neonatal adrenoleukodystrophy and infantile Refsum disease,
invariably shows the presence of C27-bile acid intermediates
and a C29-dicarboxylic acid [48,49]. This dicarboxylic acid
(3α,7α,12α-trihydroxy-27-carboxymethyl-5β-cholestane-26-
oic acid) was first identified by Parmentier et al. [50,51] and is
thought to be formed by chain-elongation of THC-CoA. Van
Eldere et al. [49] performed an extensive study on serum bile
acids among 33 patients with a peroxisome deficiency disorder
and 100 control subjects. They found that total serum bile acids
ranged from normal to fifty times increased values which
reveals the presence of cholestasis in many of these patients.
The sum of DHCA, THCA and C29-dicarboxylic acid as a
percentage of the total sum of serum bile acids ranged from less
than 5% to more than 90%. The patients with a less severe
clinical presentation (Zellweger patients with a survival of more
than 1 year and patients with neonatal adrenoleukodystrophy
and infantile Refsum disease) had, on average, less cholestasis
and a lower percentage of bile acid precursors [49]. This implies
that the extent of the peroxisome deficiency corresponds to the
extent of the deficiency in bile acid biosynthesis in these
patients. The C24-bile acids were normally conjugated, but the
C27-bile acid intermediates were only partially conjugated [49],
which is most likely caused by the low affinity of BAAT
towards C27-bile acyl-CoAs [33,52].
In urine, the C27-bile acids are also detectable, but very
striking, especially in young children, is the presence of
tetrahydroxy-5β-cholestanoic acid and sometimes even penta-
hydroxy-5β-cholestanoic acid (Fig. 4A). These hydroxyl-
groups can be present on the steroid nucleus and have been
identified as the 1β- and 6α-hydroxylated derivatives of THCA
[53,54], but microsomal hydroxylases can also form C24-, C25-
or C26-hydroxylated derivatives of THCA [55]. Hydroxylation
of THCA is an important mechanism for increasing the polarity
and thereby the urinary excretion of the C27-bile acids. The C29-
dicarboxylic acid is not always present in urine or bile, because
it is poorly excreted [51,56].
In contrast to the increased bile acid levels in serum due to
cholestasis, the C24-bile acids were strongly decreased in
duodenal fluids of three patients with Zellweger syndrome [51].
In vivo studies on the formation of bile acids in patients with
Zellweger syndrome by intravenous administration of labeled
precursors have shown that the pool size of CDCA and CAwas
markedly reduced [12,56,57].
5.2. AMACR deficiency
AMACR deficiency can be diagnosed by the exclusive
accumulation of (25R)-THCA and (25R)-DHCA [58,59] in
plasma. For comparison, the ratio (25S/25R)-THCA was
0.23±0.05 for free THCA and 0.26±0.03 for tauro-THCA
in plasma of four patients with Zellweger syndrome [58].
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enzymatically active in case of a peroxisome deficiency
disorder. Most patients with AMACR deficiency only presentafter adolescence, but one child presented at 2 weeks of age with
a deficiency of fat-soluble vitamins and cholestasis. The bile
acid abnormalities have been very well documented in this case
[59]. Consistent with cholestasis the serum bile acid concentra-
tion and the urinary bile acid excretion were elevated, whereas
the biliary bile acid concentration measured in the duodenal
aspirate was decreased (0.9 mmol/L; normal>10 mmol/L).
Overall the C27-bile acids accounted for 82.2%, 57.6% and
39.3% of the total bile acids in serum, urine and bile,
respectively. THCA was also the major bile acid found in the
feces and accounted for 72.2% of the total fecal bile acids
excreted. Just like in patients with Zellweger syndrome, many
polyhydroxylated C27-bile acids were present in urine.
5.3. DBP deficiency
The bile acid abnormalities associated with DBP deficiency
differ between the different types of DBP deficiency. Patients
with a type III deficiency, i.e. an isolated 3-hydroxyacyl-CoA
dehydrogenase deficiency, accumulate predominantly 24-OH-
THCA. Studies on the isomeric configuration revealed that the
main accumulating isomer was (24R,25R)-24-OH-THCA,
which is formed by the hydratase unit of DBP, but is not
catabolized further because of the deficiency of the dehydroge-
nase unit [60,61]. (24R,25S)- and (24S,25S)-isomers of 24-OH-
THCAwere also present [60,61]. (24R,25S)-24-OH-THCA can
be formed by AMACR from the accumulating (24R,25R)-
isomer [40], but cannot be degraded because this isomer is not
handled by the dehydrogenase unit of LBP [41]. (24S,25S)-24-
OH-THCA is formed by the hydratase unit of LBP from 24-ene-
THC-CoA but also cannot be degraded further [41]. In type
I-deficient patients (i.e. combined deficiency of both the enoyl-
CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase unit)
and presumably also in type II-deficient patients (i.e. isolated
deficiency of the enoyl-CoA hydratase unit), although this has
not been studied in detail for type II-deficient patients, only the
(24S,25S)-isomer of 24-OH-THCAwas present, formed by LBP.
DHCA, THCA and the direct substrate of DBP, 24(E)-ene-
THCA was present in all types of DBP deficiency [60,61]. In
urine, the presence of the taurine conjugate of hydroxylated 24-Fig. 4. Negative ion electrospray tandem mass spectrometric analysis of urine
bile acids and bile alcohols from A, a patient with Zellweger syndrome, B, a
patient with DBP deficiency and C, a patient with SCPx deficiency. Very
characteristic is the presence of tauro-OH-THCA (tetrahydroxy-5β-cholesta-
noic acid) (m/z 572) and taurine conjugated pentahydroxy-5β-cholestanoic acid
(m/z 588) in urine of the patient with Zellweger syndrome, the presence of the
taurine conjugate of hydroxylated 24-ene-THCA (m/z 570) and dihydroxylated
24-ene-THCA (m/z 586) in the patient with DBP deficiency, and the presence
of bile alcohol glucuronides in urine of the SCPx-deficient patient. These
compounds are not present in the urine of a control subject. The (postulated)
identity of the metabolites is as follows: m/z 514, tauro-CA; m/z 530, tauro-
OH-CA; m/z 570 tauro-OH-24-ene-THCA; m/z 572, tauro-OH-THCA; m/z
586, tauro-diOH-24-ene-THCA; m/z 588, pentahydroxy-5β-cholestanoic acid;
m/z 611, pentahydroxy-27-nor-5β-cholestane-24-one or 5β-cholestanetetrol
glucuronides; m/z 613, 27-nor-5β-cholestanepentol glucuronide; m/z 627,
hexahydroxy-27-nor-5β-cholestane-24-one or 5β-cholestanepentol glucuro-
nides; m/z, 629 27-nor-5β-cholestanehexol glucuronide; m/z 643, heptahy-
droxy-27-nor-5β-cholestane-24-one or 5β-cholestanehexol glucuronides.
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586) is characteristic for patients with DBP deficiency (Fig. 4B).
A recent study among a large cohort of DBP-deficient patients
revealed however, that in 26% of the patients no C27-bile acids
were present in plasma [62]. Similar to the situation in the
peroxisome deficiency disorders, it was shown that patients with
a longer survival tended to accumulate less THCA and DHCA,
whereas their levels of CA andCDCAwere higher. This suggests
that residual DBP activity most likely contributes to the extent of
bile acid abnormalities in the patients. This was further
substantiated by structure-based analysis of the mutated proteins
in patients with mild biochemical abnormalities [63].
5.4. SCPx deficiency
Only one patient with SCPx deficiency has been described so
far [64]. Only trace amounts of DHCA and THCAwere present
in plasma and urine of this patient. Interestingly, tandem mass
spectrometric analysis of urine consistently showed large peaks
with m/z 611 and 627, which are most likely pentahydroxy-27-
nor-5β-cholestane-24-one and hexahydroxy-27-nor-5β-choles-
tane-24-one glucuronides, respectively (Fig. 4C). These
compounds could be formed by hydroxylation and decarbox-
ylation of the substrate of SCPx, 3α,7α,12α-trihydroxy-24-
keto-cholestanoyl-CoA [65]. In addition, compounds with m/z
613 and 629 were abundantly present, which are most likely 27-
nor-5β-cholestanepentol and 27-nor-5β-cholestanehexol glu-
curonides, respectively. The presence of large amounts of bile
alcohols in urine of this patient suggests that the block in bile
acid biosynthesis at the level of SCPx may initiate the
alternative pathway for bile acid biosynthesis not requiring
peroxisomal β-oxidation; i.e. the microsomal 25-hydroxylase
pathway [45,46].
5.5. BAAT deficiency
Four members of two Amish families have been reported
with a homozygous mutation in the BAAT gene [66]. The
patients had increased serum bile acid levels and the bile acids
in serum were unconjugated. Because unconjugated bile acids
are not efficiently excreted in the bile, the bile acid concentra-
tions in the intestine were hypothesized to be very low resulting
in fat malabsorption, failure to thrive and a vitamin-K
dependent coagulopathy. Another boy had been described
previously with no glyco- or tauro-conjugated C24-bile acids,
but at that time a specific BAAT deficiency was not established
with certainty [44]. This patient had a similar clinical
presentation with cholestasis associated with high serum and
urine bile acid levels and low levels of fat-soluble vitamins.
6. Bile acid abnormalities in mouse models for peroxisomal
disorders
6.1. Mouse models for Zellweger syndrome
No studies on bile acid abnormalities in mouse models for
Zellweger syndrome have been reported yet. Reduction of theC24-bile acid levels and accumulation of C27-bile acid
intermediates have been reported as unpublished observations
in both the Pex2 knockout mouse [67] and in the hepatocyte-
selective Pex5 knockout mouse [68].
6.2. Amacr knockout mouse
Negative ionmass spectrometrywas used to analyze bile acids
in liver, bile and plasma from adult (4.5months)Amacr knockout
mice [69]. Compared to wild type animals, Amacr−/− mice
accumulated C27-bile acid precursors, whereas the levels of the
C24-bile acids were strongly decreased in liver, bile and plasma.
The major accumulating precursors were THCA and tauro-
THCA. In wild type livers, the amount of C24-bile acids and C27-
bile acid intermediates was 349±181 and 21.5±8.6 μmol/kg,
respectively, whereas in knockout livers this was 61.9±28.1 and
111±45 μmol/kg. Thus, the total amount of bile acids was also
reduced in knockout mice (370±189 μmol/kg in wild type livers
and 173±17 μmol/kg in knockout livers).
6.3. LBP, DBP and LBP:DBP knockout mice
No bile acid abnormalities have been observed in LBP
knockout mice. In contrast, the major bile acid in liver, bile and
plasma from DBP−/− mice was 24(E)-ene-THCA [34,70]. The
severity of the bile acid synthesis defect in adult DBP−/− mice
(6–10 weeks old) was similar to that in Amacr−/− mice. In
knockout livers the amount of C24-bile acids and C27-bile acid
intermediates was 43.5±10.1 and 154.1±53.6 μmol/kg, respec-
tively, and inwild type livers 347.2±176.6 and 2.74±0.74μmol/
kg [34]. A surprising observation was that the accumulating C27-
bile acids in DBP−/− mice were predominantly unconjugated
before weaning in liver, bile and plasma, whereas they were
mostly present as taurine-conjugates at adult age. This age-
dependent increase in conjugation of C27-bile acid intermediates
was in sharp contrast to the situation with the C24-bile acids,
which were already fully conjugated at postnatal day 2. This
conjugation defect of C27-bile acid was caused by a very low
expression of BAAT in mouse pups, in combination with a high
Km for C27-bile acyl-CoAs [33,34,52].
To investigate the possible role of LBP in an alternative
pathway for bile acid biosynthesis, bile acid profiles of LBP:
DBP double knockout mice were compared with those of DBP
and LBP single knockout mice [34]. Since almost no double
knockout mice survive beyond weaning, comparative analysis
in mice from all the different genotypes could only be
performed before postnatal day 21. The deficiency of C24-bile
acids was more pronounced in double knockout mice than in
DBP−/− mice, and the C27/C24-bile acid ratio was even higher.
The major accumulating C27-bile acid in DKO mice, however,
was not the direct substrate of the bifunctional proteins, 24(E)-
ene-THCA, like in DBP−/− mice, but THCA and OH-THCA.
This was the result of a deficiency of the THC-CoA oxidase in
livers from double knockout mice due to a peroxisomal import
defect [34,71]. Unfortunately, this inability to oxidize THC-
CoA prevented any conclusions to be drawn about the potential
role of LBP in a rescue pathway for bile acid biosynthesis.
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Biliary levels of bile acids were ∼20% lower in adult Scpx
knockout mice compared to wild type mice, but these
differences were not statistically significant [65]. In serum
C24-bile acids were decreased 40–60%, and an unusual bile
alcohol and some unusual bile acids were abundantly present.
These bile acids were 23-nor-CA, 23-nor-CDCA and 23-nor-
ursodeoxyCA, and they are most likely formed via α-oxidation
and 23-hydroxylation from their normal counterparts. Human
patients with cerebrotendinous xanthomatosis (CTX), which is
caused by CYP27A1 deficiency, also have elevated levels of
23-nor-bile acids [72]. The bile alcohol was identified as
3α,7α,12α-trihydroxy-27-nor-5β-cholestane-24-one, which is
formed after decarboxylation of the substrate of SCPx 24-keto-
THC-CoA, and was also present as glucuronide-conjugate in
urine from the human SCPx-deficient patient [64]. Treatment of
Scpx−/− mice with cholestyramine, which induces bile acid
synthesis, increased the concentration of 3α,7α,12α-trihy-
droxy-27-nor-5β-cholestane-24-one and of the 23-nor-bile
acids. No THCA or OH-THCA was detected in bile or serum
of Scpx−/− mice [65].
7. Pathological consequences of a peroxisomal bile acid
biosynthesis defect
Bile acid abnormalities are thought to contribute to the liver
disease and growth impairment associated with peroxisome
deficiency disorders. Patients with Zellweger syndrome have
hepatomegaly, elevated serum liver enzymes, excessive hepa-
tocyte iron stores, cholestasis and steatorrhea. Lesions of
cholangioles, inflammation and bile duct proliferation can be
present upon histological examination of the liver [73]. Many
patients with Zellweger syndrome develop fibrosis and the
patients that survive longer may develop cirrhosis [73]. Bile
acids are crucial for bile flow and absorption of dietary lipids
and fat-soluble vitamins [74]. C27-bile acids have altered
physical properties and as a consequence they might not
function properly as bile acids. They are excreted in bile, but the
low C27/C24-bile acid ratio in bile from DBP and Amacr
knockout mice compared to the ratio in liver shows that they are
not excreted as efficiently as C24-bile acids [34,69]. This is
probably at least in part due to the fact that C27-bile acids are
only partly conjugated. It has been suggested that the C27-bile
acids intermediates are especially toxic, but currently there is no
direct proof for this. It is known, however, that conjugated bile
acids are more soluble, less toxic and better promoters of dietary
lipid absorption. The contribution of the overall bile acid
abnormalities to the liver disease has been clearly established
[73,75]. Oral treatment of a 6-month-old Zellweger patient with
CA and CDCA (100 mg each per day) normalized the serum
liver enzymes and serum bilirubin, and a histological
improvement in the extent of inflammation, bile duct prolifer-
ation and cholestasis was observed [75]. Steatorrhea improved
and was accompanied by an improvement in growth. Plasma
and urinary C27-bile acids decreased after treatment [75]. The
rationale behind this treatment was i) to inhibit the endogenoussynthesis of bile acids by down-regulation of CYP7A1 and
thereby preventing further synthesis and accumulation of
potentially hepatotoxic bile acid intermediates (see the next
paragraph for detailed explanation of this feedback mecha-
nism), ii) to increase bile flow by replenishing the decreased
levels of C24-bile acids, and iii) to increase the intraluminal bile
acid concentration, thereby facilitating the absorption of fats
and fat-soluble vitamins resulting in improvement in growth. In
two Japanese patients with Zellweger syndrome treatment with
bile acids also decreased THCA levels and the serum liver
enzymes [76]. Although the success of this treatment clearly
shows the involvement of the bile acid abnormalities in the liver
pathology, it remains difficult to establish the direct effects of
these bile acid alterations because in peroxisome deficiency
disorders and also in DBP deficiency multiple peroxisomal
functions are deficient.
Most patients with AMACR deficiency [77] and the SCPx-
deficient patient [64] presented at an adult age with a
neuropathy. The neuropathy is believed to be caused by the
progressively increasing concentration of branched-chain fatty
acids, because the clinical presentation is similar to the one
observed in Refsum disease where accumulation of phytanic
acid is the only biochemical abnormality [78]. Two siblings
with AMACR deficiency, however, presented with cholestatic
liver disease in the first neonatal weeks [59]. The patients had
clear bile acid abnormalities described above, whereas the
pristanic acid levels were only minimally elevated due to their
young age. Liver pathology in the sister revealed giant cell
transformation, the prevalence of necrotic hepatocytes and
periportal hemosiderosis, and these changes resembled the
changes seen in several other bile acid synthetic defects [59,73].
Cholic acid treatment reduced C27-bile acids in urine and
markedly improved liver histology [59]. This supports the
results obtained with treatment of the patient with Zellweger
syndrome and shows that in peroxisomal disorders the defect in
bile acid biosynthesis contributes to the development of
cholestatic liver disease. It has also been postulated that the
accumulation of C27-bile acid intermediates may play a role in
the neuronal migration defect in Zellweger syndrome [79,80],
but this remains to be investigated.
8. Nuclear receptors involved in the peroxisomal steps of
bile acid biosynthesis
Bile acid homeostasis is controlled by NRs. NRs are a family
of transcription factors, which contains 48 members in human,
and are involved in the control of numerous processes,
including development and metabolism. NRs typically consist
of a DNA-binding domain and a ligand-binding domain. The
DNA binding domain binds specific so-called response
elements in the promoter of target genes. Upon ligand binding,
NRs change conformation which induces dissociation of
corepressors and the recruitment of transcriptional cofactors,
resulting in the activation of transcription. This property makes
NRs on the one hand interesting pharmaceutical targets and on
the other hand potential mediators in the pathology of disorders
in which potential ligands accumulate. In this review we will
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bile acid biosynthesis, and discuss their possible role in the
pathology and their therapeutic potential in peroxisomal
disorders with a bile acid synthesis defect.
The identification of bile acids as the endogenous ligands of
farnesoid X receptor α (FXRα, NR1H4) [81–83] was the first
proof that NRs control bile acid homeostasis. This discovery
suggested a function for FXRα in the enterohepatic recycling of
bile acids and the feedback regulation of bile acid biosynthesis,
which is in line with the reported expression pattern of FXRα in
liver and intestine [84]. In these tissues, FXRα activation
protects against accumulation of bile acids, which is toxic, by
affecting the expression of genes involved in bile acid transport,
binding and synthesis via mechanisms that have been reviewed
recently [6,85,86]. With respect to the peroxisomal part of the
bile acid biosynthesis pathway, FXRα activation has been
shown to induce the expression of BACS and BAAT in primary
rat hepatocytes and rat liver. Analysis of the human BACS and
BAAT promoter revealed FXR response elements, suggesting
that FXRα activation leads to increased conjugation of bile
acids [87]. As discussed in previous sections, BACS is localized
at the endoplasmic reticulum and is responsible for the
reactivation of free bile acids, which have been deconjugated
in the intestinal lumen. The BAAT activity localized in the
cytosol is most likely necessary for the subsequent reconjuga-
tion, whereas the BAAT activity in peroxisomes is responsible
for conjugation of newly synthesized bile acids. Thus the
coordinate FXRα-dependent induction of BACS and BAAT is
necessary for the reconjugation of bile acids. Whether this
mechanism plays a role in the peroxisomal conjugation of
newly synthesized bile acids, is questionable.
Of particular interest is short heterodimer partner (SHP,
NR0B2), which is also an FXRα target gene. SHP is an atypical
NR that only has a ligand-binding domain but no DNA-binding
domain, and inhibits the activity of several nuclear receptors.
FXRα-mediated SHP induction underlies the negative feedback
regulation of bile acid biosynthesis [88–93]. SHP binds and
interferes with the activity of liver X receptor α (LXRα,
NR1H3) [88] and liver receptor homolog-1 (LRH-1, NR5A2)
[90,91], both necessary in mice for transcriptional activation of
CYP7A1, the rate-limiting enzyme step in bile acid biosynthe-
sis. SHP induction is also the basis for the downregulation of
CYP8B1 by bile acids [94]. This elegant feed back regulation of
bile acid synthesis is the molecular mechanism behind the
decrease in plasma and urinary C27-bile acids after oral
treatment of a Zellweger patient with CA and CDCA [75,76].
Both conjugated and unconjugated bile acids are FXRα
ligands. This has been explained by analysis of the crystal
structure of FXRα. The steroid nucleus of the bile acid molecule
occupies the ligand binding pocket with the carboxylate group
oriented towards the solvent. Conjugated amino acids will be
positioned completely out of the pocket and are solvent exposed
[95,96]. It is therefore no surprise that C27-bile acid biosynthesis
intermediates are also FXRα ligands (see for the structure of
C27-bile acids Fig. 2). Of particular interest are THCA and
DHCA, which accumulate in several peroxisomal disorders
[97]. As discussed earlier, cholestasis is frequently observed inperoxisome deficiency disorders. The pathogenesis of this
symptom is unknown. FXRα stimulates expression of canalic-
ular bile acid transporters and the bile acid conjugating
enzymes, and thereby promotes excretion of bile acids into
the bile and bile flow. A defect in FXRα signaling due to
decreased levels of C24-bile acids could therefore in theory offer
an explanation for the cholestasis. In FXRα knockout mice,
however, bile formation is not affected [98]. Combined with the
fact that THCA and DHCA are bonafide FXRα ligands [97],
FXRα does not seem to play a prominent role in the
pathogenesis of cholestasis in peroxisome deficiency disorders.
Genes up- or downregulated via FXRα activation have been
profiled by microarray analysis [87]. In the published list of
genes none of the peroxisomal genes involved in bile acid
biosynthesis are present. This may not come as a surprise
because the main regulated enzyme in bile acid biosynthesis is
the rate-limiting CYP7A1. Moreover, the peroxisomal enzymes
involved in bile acid biosynthesis, AMACR, BCOX, DBP and
SCPx, also exert other functions not related to bile acid
synthesis. In conclusion, although FXRα is the main regulator
of bile acid homeostasis, evidence that it controls the
peroxisomal steps is currently lacking.
Recently, the role of hepatocyte nuclear factor 4α (HNF4α;
NR2A1) in bile acid biosynthesis was studied in detail [99].
Initial studies of a liver specific HNF4α knockout mouse
already demonstrated a role in bile acid homeostasis. These
mice had increased serum levels of bile acids most likely caused
by reduced expression of basolateral bile acid transporters
[100]. Follow-up studies showed decreased expression of
BACS and BAAT leading to changes in bile acid conjugation
[101]. Expression of Cyp7a1, Cyp7b1, Cyp8b1, Cyp27a1,
Acox2 (encoding THC-CoA oxidase) and Scpx, all bile acid
biosynthetic genes, was also decreased. Despite these changes,
bile acid pool size and composition were only mildly affected
[101]. HNF4α binds to the promoter of about 12% of all tested
genes expressed in liver [102]. Most of these promoters are also
occupied by RNA polymerase II. Thus HNF4α is rather a
widely acting, constitutively active transcription factor in liver
than a specific regulator of bile acid homeostasis.
Pregnane X receptor (PXR, NR1I2, also referred to as steroid
and xenobiotic receptor, SXR) is a NR expressed in liver and
intestine and is involved in the metabolism of potentially toxic
foreign chemicals, often referred to as xenobiotics [103]. PXR is
also involved in bile acid homeostasis. First of all lithocholic
acid (LCA), a secondary bile acid derived from CDCA, activates
PXR. LCA acid is a hydrophobic bile acid that causes cholestasis
when administered to animals. Detoxification of LCA is
achieved by 6α-hydroxylation (mediated by cytochrome P450
3A, CYP3A [104]) and conjugation, pathways known to be
activated by PXR. Indeed, activation of PXR by LCA or a
synthetic ligand (pregnenolone 16α-carbonitrile, PCN) stimu-
lates uptake and metabolism of LCA in the hepatocyte via
upregulation of the organic anion transporting protein 2
(OATP2, Slc21a5) and CYP3A [105–108]. More importantly,
LCA-induced liver damage can be reduced by coadministration
of PCN [107,108], but also in bile duct ligation, a more
physiologic cholestasis model, Cyp3a upregulation via PXR
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addition, PXR prevents hepatorenal toxicity from cholesterol
metabolites [111].
Detoxification of bile acid precursors plays an important role
in Cyp27a1 knockout mice [112]. The bile acid intermediates
that accumulate in these mice, 5β-cholestane-3α,7α,12α-triol
and 7α-hydroxy-4-cholesten-3-one, also activate PXR [113,114].
Interestingly, these metabolites are more potent activators of
mouse PXR when compared with human PXR, which may
explain why human CTX patients fail to increase CYP3A
activity [113,114]. The upregulation of Cyp3a in Amacr
knockout mice [69] suggests that similar to the situation in the
Cyp27a1 knockout mouse, the accumulated C27-bile acids
activate mouse PXR. In the Pex2 knockout mouse, however,
Cyp3a expression was decreased [67]. In vitro studies are
therefore necessary to assess if peroxisomal bile acid metabolites
can activate human and mouse PXR. As discussed before,
tetrahydroxylated and pentahydroxylated C27-bile acids are
present in urine of patients with several different peroxisomal
deficiencies. These include 6α-hydroxylated C27-bile acids,
which are potential products of CYP3A metabolism. The large
amounts of bile alcohols in the SCPx-deficient patient may be
explained by the induction of xenobiotic metabolism. It is
unknown if C27-bile acid hydroxylation is induced via PXR
activation as a defense mechanism to reduce their toxicity.
Increasing the hydroxylation will promote the urinary excretion
of C27-bile acids and as a consequence liver pathology might be
ameliorated in peroxisome deficiency disorders.
Recently, studies with the synthetic LXR agonist T0901317
revealed that peroxisomal β-oxidation is regulated by LXRα
[115]. The LXR agonist induced the genes encoding straight-
chain acyl-CoA oxidase (ACOX1), LBP (EHHADH) and the
classic 3-ketoacyl-CoA thiolase (ACAA1). Given the fact that
the bile acid synthesis pathway uses BCOX, DBP and SCPx,
the other peroxisomal β-oxidation enzymes, it is not expected
that LXR activation directly affects the peroxisomal steps in bile
acid synthesis. In addition DHCA did not activate LXR [97].
Bile acids have been reported to signal also via alternative
pathways, including other NRs, such as the vitamin D receptor
(VDR, NR1I1) and constitutive androstane receptor (CAR,
NR1I3), and non-NR pathways including mitogen-activated
protein kinase (MAPK) pathways [116,117] and the G-protein-
coupled receptor (GPCR) TGR5 [118,119]. So far the effect of
bile acid precursors on these signaling routes has not been
studied.
9. Concluding remarks
Almost all peroxisomal steps in bile acid biosynthesis have
been resolved in the past years by studies with recombinant
enzymes and studies in material from patients and different
mouse models. The transporters in the peroxisomal membrane,
however, for the C27-bile acid intermediates and the conjugated
C24-bile acids are still unknown. Other important questions that
remain are: i) How are the residual C24-bile acids formed in
patients with a peroxisomal bile acid synthesis defect? Which
alternative pathway is involved and can this pathway perhaps beinduced? ii) Are the bile acid abnormalities also involved in the
development of the neurological symptoms associated with
peroxisomal disorders and not only in the pathology of the
liver? Are the C27-bile acid intermediates toxic in this respect?
iii) Is modulation of the transcriptional control of bile acid
homeostasis a potential therapy for these disorders? Induction
of xenobiotic metabolism of bile acids via PXR activation might
be a therapeutic option in analogy to the situation in CTX
patients. However, feedback inhibition of bile acid biosynthesis
via bile acid supplementation and the resulting FXRα activation
seems to be far more promising. Although the peroxisomal steps
in bile acid biosynthesis are not downregulated after FXRα
activation, the decrease in the rate limiting CYP7A1 activity
decreases the flux through the bile acid biosynthesis pathway
thereby decreasing the levels of C27-bile acids. The replenished
C24-bile acids increase bile flow and stimulate the absorption of
fat and fat-soluble vitamins.
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